Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxart, Inc. - Common Stock (NQ:VXRT)

0.3200 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum ↗
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19. 
Via InvestorPlace
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
News headline image
It’s Time to Start Thinking Seriously About Vaxart ↗
While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration. 
Via InvestorPlace
Topics Government
Unusual Options Activity Insight: Vaxart ↗
Vaxart (NASDAQ:VXRT) shares experienced unusual options ac... 
Via Benzinga
Unusual Options Activity Insight: Vaxart ↗
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options a... 
Via Benzinga
News headline image
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern ↗
Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a... 
Via Benzinga
News headline image
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look ↗
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
News headline image
Is Vaxart Stock Really Worth a Shot? ↗
VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine). 
Via InvestorPlace
News headline image
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices ↗
Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained since, but it's still too pricey. 
Via InvestorPlace
News headline image
Vaxart Is Another Risky Biotech Stock to Avoid Right Now ↗
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares. 
Via InvestorPlace
News headline image
The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine ↗
With many unvaccinated and the Delta variant a growing danger, VXRT stock has a good chance to increase in value in the coming future. 
Via InvestorPlace
News headline image
Vaxart Stock Probably Isn’t Worth the Risk as It Pushes Higher ↗
Vaxart’s oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen. 
Via InvestorPlace
News headline image
Why Shares of Vaxart Are Soaring Today ↗
Some encouraging news for this troubled biotech. 
Via The Motley Fool
News headline image
28 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of... 
Via Benzinga
News headline image
The Bull Thesis for VXRT Stock is Questionable at Best ↗
Vaxart is far too risky for far too little 
Via InvestorPlace
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia
News headline image
Why Vaxart's Stock Price Is Being Compressed In A Pennant Pattern And Looks Ready To Break Soon ↗
Vaxart Inc. (NASDAQ: VXRT) shares pushed higher Monday after the company made an announcement stating the U.S. Food and Drug Administration cleared its Investigational New Drug... 
Via Benzinga
News headline image
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today ↗
VXRT stock is bulking up today. The company is getting approval from the FDA regarding its Covid vaccine, allowing for further research. 
Via InvestorPlace
News headline image
Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate ↗
The FDA has signed off Vaxart Inc's (NASDAQ: VXRT) Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. "This is... 
Via Benzinga
News headline image
Why Vaxart's Stock Is Trading Higher Today ↗
Vaxart Inc (NASDAQ: VXRT) is trading higher Monday morning after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug... 
Via Benzinga
News headline image
Understanding Vaxart's Unusual Options Activity ↗
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $7.91. Sentiment: BEARISH Option... 
Via Benzinga
News headline image
Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject ↗
Vaxart Inc's (NASDAQ: VXRT) has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost... 
Via Benzinga
News headline image
Why Vaxart's Stock Is Surging Higher Today ↗
Vaxart Inc (NASDAQ: VXRT) is trading higher Thursday morning after the company announced that it has shown, for the first time in clinical trials, that its oral tablet... 
Via Benzinga
News headline image
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill ↗
You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs. 
Via InvestorPlace
News headline image
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain ↗
Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy. 
Via InvestorPlace
News headline image
Why Shares of Vaxart Jumped 31.2% in the First Half of 2021 ↗
The first half has been a cycle of hope and disappointment for shareholders. 
Via The Motley Fool
News headline image
Why Coronavirus Stocks Are Zooming Higher Today ↗
The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. 
Via The Motley Fool
Topics Death
News headline image
3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street ↗
Analysts' high-water price targets imply some serious gains for these companies. 
Via The Motley Fool
Topics Economy
News headline image
Don’t Count on a Covid-19 Boost for Vaxart ↗
VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day. 
Via InvestorPlace
News headline image
New Developments Have Made Vaxart Stock So Much More Attractive ↗
Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.